M. Curtin

发表

Histone deacetylase inhibitors: the Abbott experience.

K. Glaser, M. Curtin, 2003, Current medicinal chemistry.

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

K. Glaser, S. Davidsen, V. Stoll, 2005, Journal of medicinal chemistry.

Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families

K. Glaser, S. Davidsen, C. Tse, 2012, Journal of Pharmacology and Experimental Therapeutics.

Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.

S. Davidsen, P. Tapang, D. Albert, 1998, Journal of Medicinal Chemistry.

Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.

S. Davidsen, M. Michaelides, P. Tapang, 2001, Bioorganic & Medicinal Chemistry Letters.

The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.

S. Davidsen, C. Wegner, P. Tapang, 1998, The Journal of pharmacology and experimental therapeutics.

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.

S. Davidsen, P. Tapang, D. Albert, 1997, European journal of pharmacology.

Vitamin D (calciferol) and its analogs. 40. 1.alpha.,25-Dihydroxyprevitamin D3: synthesis of the 9,14,19,19,19-pentadeuterio derivative and a kinetic study of its [1,7]-sigmatropic shift to 1.alpha.,25-dihydroxyvitamin D3

M. Curtin, W. Okamura, 1991 .

Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.

K. Glaser, C. Tse, M. Michaelides, 2012, Bioorganic & medicinal chemistry letters.

Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.

K. Glaser, S. Davidsen, C. Tse, 2012, Bioorganic & medicinal chemistry letters.

Thienopyridine urea inhibitors of KDR kinase.

K. Glaser, S. Davidsen, N. Soni, 2007, Bioorganic & medicinal chemistry letters.

Bis(trimethylsilyl)acetylene

M. Curtin, Cheng Wang, 2008 .

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

C. Tse, K. Longenecker, P. Richardson, 2017, Molecular Cancer Therapeutics.

Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.

S. Davidsen, D. Albert, M. Curtin, 1998, Bioorganic & medicinal chemistry letters.

Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.

S. Davidsen, M. Michaelides, D. Albert, 2001, Bioorganic & medicinal chemistry letters.

Current status of platelet-activating factor antagonists

M. Curtin, 1998 .

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Ana L. Aguirre, Mikkel A. Algire, C. Tse, 2017, Bioorganic & medicinal chemistry letters.

Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors.

S. Davidsen, D. Albert, M. Curtin, 1999, Journal of enzyme inhibition.

Trifluoromethyl ketones as inhibitors of histone deacetylase.

K. Glaser, S. Davidsen, M. Michaelides, 2002, Bioorganic & medicinal chemistry letters.

n‐Butyllithium–Boron Trifluoride Etherate

M. Curtin, 2001 .

Studies on the Synthesis of Nargenicin A1: Highly Stereoselective Synthesis of the Complete Carbon Framework via the Transannular Diels−Alder Reaction of an 18-Membered Macrolide

K. Koyama, W. Roush, M. Curtin, 1996 .

Synthetic and kinetic studies of the intramolecular Diels-Alder reactions of cycloalkenylallenylphosphine oxides

M. Curtin, W. Okamura, 1990 .

7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.

K. Glaser, S. Davidsen, N. Soni, 2008, Journal of medicinal chemistry.

Isoindolinone ureas: a novel class of KDR kinase inhibitors.

K. Glaser, S. Davidsen, M. Michaelides, 2004, Bioorganic & medicinal chemistry letters.

Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).

K. Glaser, S. Davidsen, M. Michaelides, 2002, Bioorganic & medicinal chemistry letters.

Recent advances in matrix metalloproteinase inhibitors research.

M. Michaelides, M. Curtin, 1999, Current pharmaceutical design.

Triphenylchloromethane (trityl chloride)

M. Curtin, 2003 .

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

K. Glaser, S. Davidsen, C. Tse, 2011 .

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

Jun Guo, Kenneth M Comess, Haizhong Zhu, 2017, Nature chemical biology.

From one well to 9000: using high-density streptavidin-coated membranes for kinase detection.

S. Goueli, M. Curtin, J. Watson, 2002, BioTechniques.

Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.

Yan Guo, Yujia Dai, S. Davidsen, 2002, Journal of medicinal chemistry.

Differential protein acetylation induced by novel histone deacetylase inhibitors.

K. Glaser, M. Staver, S. Davidsen, 2004, Biochemical and biophysical research communications.

Current patent status of histone deacetylase inhibitors

M. Curtin, 2002 .

CHOOSING THE BEST KINASE ASSAY TO MEET YOUR RESEARCH NEEDS

M. Curtin, 2005 .

Alpha-keto amides as inhibitors of histone deacetylase.

K. Glaser, S. Davidsen, P. Richardson, 2003, Bioorganic & Medicinal Chemistry Letters.

Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.

S. Muchmore, H. Sham, M. Curtin, 2003, Bioorganic & medicinal chemistry letters.

Expression and functional characterization of recombinant human HDAC1 and HDAC3.

K. Glaser, M. Staver, S. Davidsen, 2004, Life sciences.

A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.

K. Glaser, S. Davidsen, M. Michaelides, 2003, Bioorganic & medicinal chemistry letters.

Heterocyclic ketones as inhibitors of histone deacetylase.

K. Glaser, S. Davidsen, A. Vasudevan, 2003, Bioorganic & medicinal chemistry letters.

α-Keto amides as inhibitors of histone deacetylase

Paul L. Richardson, Zhiqin Ji, Jun Guo, 2003 .

The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.

S. Davidsen, D. Albert, M. Curtin, 1998, Bioorganic & medicinal chemistry letters.

SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.

Hongyu Zhao, Ying Wang, Zhiqin Ji, 2017, Bioorganic & medicinal chemistry letters.

Discovery and Evaluation of a Series of 3‐Acylindole Imidazopyridine Platelet‐Activating Factor Antagonists.

M. Curtin, 1998 .

Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.

M. Curtin, 2004, Current opinion in drug discovery & development.

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

Mikkel A. Algire, Justin D Dietrich, A. Petros, 2017, Nature chemical biology.

SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.

Mikkel A. Algire, Justin D Dietrich, P. Richardson, 2017, Bioorganic & medicinal chemistry letters.